Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.
Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.
The results were simultaneously published in The New England Journal of Medicine.1
A substantial amount of evidence exists linking diabetes with heart disease, and The Framingham Heart Study was the first to show that patients with type 2 diabetes are more susceptible to heart disease. Aspirin use has, of course, been found to benefit patients with cardiovascular (CV) disease, and joint guidelines2 developed by the American Heart Association and the American College of Cardiology Foundation recommend a 75- to 162-mg daily dose of aspirin in all patients with coronary artery disease.
However, the value of this antiinflammatory agent in preventing the first CV event in patients undergoing treatment for diabetes remains unknown.
Read how adding sulfonylureas to metformin can reduce CV risk in diabetes.
The ASCEND trial was designed to randomly assign 15,480 adults with diabetes to receive 100 mg of aspirin daily, or a matching placebo. Trial participants did not have any hint of CV disease. Efficacy and safety were monitored and measured as the first serious vascular event (myocardial infarction, stroke, or transient ischemic attack; or death from any vascular cause, excluding any confirmed intracranial hemorrhage) and the first major bleeding event (intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding), respectively. Gastrointestinal (GI) tract cancers were monitored as secondary outcomes.
Following a mean follow-up period of 7.4 years, significantly lower serious vascular events were observed in the aspirin group compared to the placebo group (658 [8.5%] vs 743 [9.6%]; relative risk [RR], 0.88; 95% confidence interval [CI], 0.79-0.97; P = .01). Bleeding events, however, were observed at a much higher rate in the aspirin-treated group (n = 314, 4.1%) compared to the placebo group (n = 245, 3.2%) (RR, 1.29; 95% CI, 1.09-1.52; P = .003).
While the trial continues to monitor long-term outcomes for GI cancers, at the time of the current analysis, the incidence rate was comparable between the treatment and placebo groups (157 [2.0%] and 158 [2.0%], respectively).
“Even though we showed clearly that aspirin reduces the risk of vascular events, including heart attacks, strokes, and mini-strokes, it also increased the risk of major bleeds, mainly from the gastrointestinal tract, so overall there was no clear benefit,” said Jane Armitage, FRCP, FFPH, principal investigator, Nuffield Department of Population Health, University of Oxford, United Kingdom, in a statement. “It had been suggested that low-dose aspirin might protect against cancer, but we saw no reduction in any cancers; we are continuing to follow the participants to see whether any benefits appear later.”
According to Armitage, their study results provide “much needed clarity” to existing guidelines, which vary in their recommendations of using aspirin for the primary prevention of CV events in patients with diabetes.
References
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen